• Safety Review Committee clears progression to cohort 5
• No safety signals reported across first four cohorts
• Amended protocol allows for higher doses and longer infusion duration

Nyrada Inc. (ASX:NYR), a clinical stage drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel inhibitors, has provided an update on its Phase I clinical trial for its lead candidate, Xolatryp. The company confirms that the Safety Review Committee (SRC) for the Phase I trial has reviewed data from the first four cohorts and has provided clearance to proceed to the fifth cohort. No safety signals, dose-limiting toxicities, or unexpected side effects were reported across the dosed cohorts. The amended Phase I trial will now comprise six (6) cohorts and allow for the evaluation of Xolatryp at higher doses and over a longer infusion duration. Final trial readouts are still expected in the quarter ending September 2025. Xolatryp has demonstrated preclinical efficacy as an acute treatment following ischemic stroke, traumatic brain injury (TBI), and acute myocardial infarction (AMI). The company has previously announced positive results from preclinical studies in these indications.